A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint

Rodolfo E. De la Vega, Jacob L. Sellon, Jay Smith, Stephen J. Wisniewski, Mary L. Jurisson, Matthew A. Frick, Tyson L. Scrabeck, Julie B. Block, Candee J. Mills, Zachary W. Pohlkamp, Michael J. Coenen, Gresin P. Hawse, Temilola Y. Abdul, Philip Conaghan, Annahita Keravala, Thomas W. Chalberg, Paul D. Robbins, Steven C. Ghivizzani, Christopher H. Evans

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)–recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 1011 viral genomes (vg)], mid (1 × 1012 vg), or high (1 × 1013 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.

Original languageEnglish (US)
Article numbereadu9804
JournalScience Translational Medicine
Volume17
Issue number801
DOIs
StatePublished - Jun 4 2025

Bibliographical note

Publisher Copyright:
Copyright © 2025 The Authors, some rights reserved;

Fingerprint

Dive into the research topics of 'A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint'. Together they form a unique fingerprint.

Cite this